Author: miracellPH

Ewha Medical Center Establishes a “Convergence Healthcare Technology Development Hub”

▲ ⓒEwha Medical Center Ewha Womans University Medical Center is accelerating the construction of a cutting-edge convergence healthcare technology development hub (R&BD HUB). On the 7th, Ewha Medical Center held an opening ceremony for the Industry-Academia Cooperation Center and a joint business partnership agreement signing ceremony with participating companies in the conference rooms on the 6th and 10th floors of Building B of the Medical Building at Ewha Mokdong Hospital, kicking off the project. The “Ewha Advanced Convergence Medical Cluster” is a project led by Ewha Medical Center, Ewha Womans University, and Ewha College of Medicine. The project aims to build an international, cutting-edge convergence healthcare technology development hub through collaboration between industry, academia, research, and hospitals. The Ewha Medical Center Research Promotion Team recruited companies for the industry-academia collaboration three times from last year to this year. A total of 10 companies were selected. The Ewha Advanced Convergence Healthcare Cluster Industry-Academia Cooperation Center was established on the 6th and 7th floors of Building B of the Medical Building at Ewha Mokdong Hospital. The Industry-Academic Cooperation Center consists of the BT (Biotechnology) Business Center on the 6th floor and the IT (Information Technology) Business Center on the 7th floor. Resident companies will receive support from the Ewha Medical Center Research Promotion Center for shared research equipment (equipment use training), access to laboratory animal rooms, access to amenities, and networking programs. The companies include: ▲Ewireliner Co., Ltd. (Jeon Yun-sik), ▲Skia Co., Ltd. (Lee Jong-myeong), ▲Cellmit Co., Ltd. (Park Gil-jun), ▲Miracell Co., Ltd. (Shin Hyun-soon), ▲Vastera Co., Ltd. (Kang Sang-won), ▲Nexion Biotech Co., Ltd. (Seo Jeong-taek, Kim Seong-wook), ▲IQURE B&P Co., Ltd. (Choi Young-kwon), ▲Synergy AI Co., Ltd. (Shin Tae-young), ▲Neurosona Co., Ltd. (Seo Seon-il), and ▲MyCheckup Co., Ltd. (Lee Hang-gu). Ewha Medical Center and the ten companies in residence signed this MOU, covering collaboration in new drug development clinical trials, basic medical research and industrialization, and other areas of mutual agreement. Ewha Medical Center President Yoo Kyung-ha said, “We welcome the companies joining the Ewha Advanced Convergence Healthcare Cluster Industry-Academic Cooperation Center, which will emerge as a global, cutting-edge convergence healthcare hub. We will do our best to become a leading company in the biomedical industry by promoting medical technology commercialization and revitalizing R&D activities.” Reporter Park Geun-bin ray@newdailybiz.co.kr Original article link: http://biz.newdaily.co.kr/site/data/html/2020/07/08/2020070800139.html

Miracell Launches Stem Cell Storage Service on Home Shopping

[Daily Medi Reporter Park Dae-jin] Stem cell specialist Miracell (CEO Shin Hyun-soon) is garnering attention by launching an “immune stem cell extraction and storage service” on a home shopping channel. “Cell extraction and storage service” refers to the storage of immune cells and stem cells for disease treatment. While several companies are currently involved in the cell storage industry, Miracell is the first to reach consumers through a home shopping channel. Miracell is the first stem cell specialist in Korea to register autologous stem cell therapy as a new medical technology and receive notification from the Ministry of Health and Welfare. It has also registered six additional autologous stem cell therapies. While stem cell therapy has traditionally been a privilege reserved for a select few, Miracell’s service offers a unique advantage: a monthly subscription of 62,000 won for 60 months, made possible through a partnership with a rental company. The company also offers a variety of free tests to assess current and future health indicators. Miracell leverages cell extraction technology developed by the IDI Immunology Institute at Harvard Medical School. Using Harvard’s expertise, the company calculates precise cell density and extracts and stores optimal cells. A company representative stated, “We extract and store not only immune cells and stem cells, but also large amounts of growth factors and SDF-1α, a signaling molecule that helps stem cells migrate to the treatment site.” This cell storage service product is available domestically and is particularly safe because it does not require a culture process. Cultured cells have been limited to domestic and international procedures due to the risk of genetic modification and infection, and their safety has not been proven. Miracell has resolved this issue. Furthermore, excellent cells obtained through individual cell count tests are frozen and stored in liquid nitrogen tanks for 20 years, with the option to extend the storage period. This cell storage service product is stored directly by the Miracell Bio Research Institute and is covered by DB Insurance for up to KRW 200 million in damages resulting from deterioration, damage, or loss during storage. Miracell CEO Shin Hyun-soon said, “With a sense of mission to overcome disease and lead a healthy life, we launched a cell extraction and storage service that offers one-stop service from subscription to storage and use.” Meanwhile, the home shopping channel can be found on Olleh TV channel 44, SK Broadband channel 31, LG U+ channel 36, and Skylife channel 30. Original article link: http://www.dailymedi.com/detail.php?number=858293&thread=22r05

Stem cell injections may help boost immunity.

[JoongAng Ilbo, April 2, 2020] Many people are interested in strengthening their immune system to combat viruses. With the recent announcement of a case of stem cell treatment for a COVID-19 patient, some are predicting that stem cells can regenerate damaged tissue and boost immunity. While rising temperatures and rain are known to be detrimental to COVID-19 survival, this does not mean it will be eradicated. Some experts predict that the virus could multiply in the relatively cold Southern Hemisphere during summer, and then spread to the Northern Hemisphere during winter. According to experiments conducted by the National Institutes of Health, the virus survived in aerosols for more than three hours, on plastic and stainless steel surfaces for more than three days, on cardboard for more than 24 hours, and on copper for more than four hours. While the spread of COVID-19 may slow down somewhat in the summer months with rising temperatures, we cannot be complacent. It is crucial to build up our immunity to overcome any virus. [The process of extracting stem cells by collecting blood] The medical staff at the stem cell regeneration clinic, Selfia, stated, “Recent research shows that stem cells possess self-renewal and pluripotent differentiation capabilities, allowing them to differentiate into any tissue in the body. Furthermore, extracting adult stem cells from one’s own blood, bone marrow, or fat and transplanting them into the body can be utilized with minimal side effects.” They added, “In particular, intravenous administration of stem cells and various growth factors contained in their exosomes can regenerate damaged tissue through their homing effect, promoting immune system enhancement through communication between immune cells in the tissue.” They added, “These stem cell treatments are used not only to enhance immunity, but also for various other purposes, such as strengthening blood vessels, treating pain, and regenerating skin. It is crucial to receive treatment from a medical professional with extensive clinical experience.” By Kim Jin-woo (kim.jinwoo.ja@gmail.com)

Miracell Launches Special Service for Overseas Medical Consumers Traveling for Immune Stem Cell Treatment

[Financial News 2020.02.26] [Edaily Reporter Lee Soon-yong] As the novel coronavirus (COVID-19) pandemic continues, interest in boosting immunity as a means of preventing infection is growing more than ever. Amidst this, a program offering “Immune Stem Cell IV Injections and Immune Cell Maintenance” is attracting attention, offering both injection and storage services to prevent infection risks. The company behind this highly anticipated program is Miracell Co., Ltd. (CEO Shin Hyun-soon). Miracell has received approval from the Ministry of Food and Drug Safety and the Ministry of Health and Welfare for a specialized technology that extracts, separates, and concentrates blood or bone marrow stem cells. While some people previously spent significant amounts of money traveling to China and Japan to receive stem cell and immune cell injections, the global emergency caused by COVID-19 has now forced air travel to be halted for the first time in recorded history. Considering this situation, Miracell has established a special financial program to provide emergency support for immune stem cell IV injections and immune cell maintenance and storage. This program, called Miracell 240, has significantly relaxed payment terms to make it more accessible to consumers. CEO Shin Hyun-soon explained, “We’ve developed a convenient program for emergency immune stem cell IV injections and immune cell maintenance through agreements with financial institutions.” This program utilizes safe autologous stem cells and immune cells directly through minimal manipulation. It injects total cells, including growth cells, platelets, various immune cells, and hematopoietic stem cells, ensuring the freshest cells are injected directly in the required dose. Specifically, immune status is checked through an NK cell activity test prior to injection, and then repeated approximately 10 days later to ensure a consistent immune response. CEO Shin emphasized, “There are many questions about side effects, but because we use autologous cells, the risk of side effects is very low.” Experts in preventive medicine explain that maintaining good health while in good health can lead to a long and healthy life. Going forward, the global medical market will likely focus on preventive healthcare, driven by an aging population. Miracell’s medical device systems are already in use globally in 36 countries, including the United States. These FDA- and KFDA-approved medical devices are widely used in operating rooms at hospitals and clinics. A platform has been developed to support hospitals and clinics nationwide, offering a safe system that is currently being tested with approximately 200 hospitals and clinics. CEO Shin Hyun-soon stated, “I hope Miracell’s program will be of some help to the public, who are hesitant due to the risk of infection caused by COVID-19.” Lee Soon-yong (sylee@edaily.co.kr)

The efficacy of autologous bone marrow-derived stem cell injections in refractory plantar fasciitis

[Medipana News 2019-12-5] Study on the Efficacy of Autologous Bone Marrow-Derived Stem Cell Injections for Intractable Plantar Fasciitis A Prospective, Randomized, Controlled TrialDong-Woo Shim, Department of Orthopedics, International St. Mary’s HospitalPlantar fasciitis is a common, chronic foot condition that can lead to functional impairment. While the exact pathophysiology remains unknown, increased proximal fascial thickness, decreased blood flow, peritendon inflammation, and changes in pain receptors are believed to contribute to the symptoms. Pain is typically most severe with the first step in the morning, persisting or improving throughout the day, and worsening during daily activities. Bilateral plantar fasciitis occurs in 10% of patients, and more than 80% improve within one year with conservative treatment alone. Given this natural course, most patients improve without specific treatment. However, approximately 10% of patients who receive conservative treatment experience persistent pain. Therefore, patients complaining of hindfoot pain are treated with stretching exercises, shoe correction, steroid injections, autologous blood injections, extracorporeal shock wave therapy, nighttime orthotics, and non-inflammatory analgesics. If these conservative treatments fail to improve symptoms, surgical treatments such as plantar fascia release may be considered. However, the pros and cons of these treatments vary widely among authors.Stem cell therapy has recently gained attention and has been proposed as a treatment option for osteochondral injuries of the talus. While clinical data are limited, Ambrosi et al. reported significant clinical improvement after administering autologous adipose-derived stem cells to four patients with talar osteochondral injuries. However, there are no studies on the efficacy of stem cell therapy for tendon inflammation, such as plantar fasciitis. This study aims to report on the differences in treatment outcomes between stem cell therapy and other treatments for patients with refractory plantar fasciitis, in whom symptoms persist despite appropriate conservative treatment. 1. If you agree to participate in the study, blood tests, an electrocardiogram, and a chest X-ray will be performed to assess your overall health, similar to traditional surgical preparation. This study will involve a total of 18 participants. The expected follow-up period is 12 months. Four hospital visits will be required during this period: at 6 weeks, 3 months, 6 months, and 1 year. The medications and devices used in this clinical study are supplied by Miracell Co., Ltd., and are used to extract autologous bone marrow-derived stem cells for the purpose of regenerating cartilage in patients with cartilage damage. This device is a medical device approved by the Ministry of Food and Drug Safety for the treatment of cartilage damage. This clinical study will evaluate its effectiveness in treating inflammation in tendons and tendon tissues, including the fascia. For inquiries, contact: Dong-Woo Shim, Department of Orthopedics, International St. Mary’s Hospital Email: dcastle@hanmail.net <ⓒ 2019 Medipana News. Unauthorized reproduction and distribution prohibited>Medipana News, the “center of Korean medical news.”

Miracell, boosting immunity with stem cell intravenous injections. Miracell, boosting immunity with stem cell intravenous injections.

[Financial News 2020.02.26] Miracell boosts immunity with intravenous stem cell injections. [Financial News] With much attention focused on strengthening immunity to prevent COVID-19, there are cases where immunity was enhanced through intravenous stem cell injections. Dr. Choi Dong-jin, director of Selfia Clinic, announced on the 26th that a patient complaining of chronic fatigue and physical decline experienced an increase in NK cell counts after receiving stem cell treatment from Miracell.NK cells actively seek out cancer cells or virus-infected cells and induce their apoptosis or necrosis. Numerous studies have concluded that NK cells inhibit cancer progression not through their numbers, but through their activity. The procedure involves extracting 240cc of the patient’s blood, separating and concentrating it, extracting stem cells, and then injecting them intravenously. Stem cells can create cells with the same capabilities as themselves through cell division. This regenerative ability allows them to regenerate body tissues and organs. Dr. Choi compared immune cell activity by testing NK cell activity 10 days after the intravenous stem cell injection. The immune cell count before the stem cell injection was 447.6, while the count after the injection was 1542.2, representing a nearly threefold increase. Director Choi explained that to enhance NK cell activity, it is recommended to combine stem cell injections with regular exercise, adequate sleep and rest, hydration, and antioxidant intake. Pompom@fnnews.com, Reporter Jeong Myeong-jin

Miracell Launches Cell Storage Service Rental Product

[Maeil Business Newspaper, March 16, 2020] Miracell Co., Ltd. Launches Immune Cell and Stem Cell Storage Rental Products to Strengthen Immunity Stem cell specialist Miracell Co., Ltd. (CEO Shin Hyeon-sun) and rental service specialist Barorental (CEO Lee Hyeong-bae) announced the official launch of a 20-year cell storage rental service (‘Immune Cell/Stem Cell Barobaro Care’) to strengthen immunity and provide healthcare. The newly launched “Cell Storage Rental Service” is a service that isolates stem cells and immune cells from healthy adults and freezes them for 20 years. This service is a future-oriented healthcare service that preserves the body’s immune system, which plays a crucial role in the fight against infectious diseases like COVID-19, SARS, and MERS. By launching Korea’s first “immune cell/stem cell storage rental product,” CEO Lee Hyung-bae of Barorental Co., Ltd. has dedicated himself to minimizing customer costs and making cell storage rental products more accessible to a wider audience. He expressed his hope that this service will help people overcome health concerns and anxiety about future illnesses during these challenging times, and expressed his ambition to introduce the “cell storage rental product” through various channels. Shin Hyun-soon, CEO of Miracell, a domestic stem cell company, said, “The efforts to popularize and expand regenerative medicine using stem cells and immune cells over the past decade have recently been re-evaluated due to the COVID-19 pandemic.” He added, “Government support is urgently needed to revitalize the future bio-regenerative medicine market. Furthermore, as infectious diseases like the current one spread, we must devise measures to protect our health.” He emphasized that now, with the growing sense of crisis surrounding individual immunity, is the perfect time to store healthy immune cells to prepare for unknown diseases that may arise in the future. Detailed information on cell storage rental products can be found on the official websites of Miracell and Barorental. [ⓒ Maeil Business Newspaper & mk.co.kr, Unauthorized reproduction and redistribution prohibited]